×

What Roche gets from InterMune

10:09 AM ET Mon, 25 Aug 2014

Switzerland's Roche is buying InterMune for $8.3 billion. CNBC's Meg Tirrell reports InterMune's Esbriet drug could draw more than $1 billion in annual revenue.